Abstract OT2-1-08: A phase II open label study of everolimus in combination with anti-estrogen therapy in hormone receptor-positive HER2-negative advanced breast cancer

2015 ◽  
Author(s):  
Denise A Yardley ◽  
Mythili Shastry ◽  
Laura M DeBusk ◽  
Howard A Burris III ◽  
John D Hainsworth
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Estrogen Therapy ◽  
Advanced Breast ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Hormone Receptor Positive

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer

The Breast ◽  
2013 ◽  
Vol 22 (4) ◽  
pp. 470-475 ◽  
Author(s):  
Matteo Clavarezza ◽  
Monica Turazza ◽  
Enrico Aitini ◽  
Silvana Saracchini ◽  
Ornella Garrone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Phase II open-label study of sunitinib in patients with advanced breast cancer

2012 ◽  
Vol 136 (3) ◽  
pp. 759-767 ◽  
Author(s):  
Denise A. Yardley ◽  
E. Claire Dees ◽  
Stephen D. Myers ◽  
Sherry Li ◽  
Paul Healey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Advanced Breast ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

2018 ◽  
Vol 24 (18) ◽  
pp. 4380-4387 ◽  
Author(s):  
Maura N. Dickler ◽  
Cristina Saura ◽  
Donald A. Richards ◽  
Ian E. Krop ◽  
Andrés Cervantes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Study ◽  
Advanced Breast ◽  
Hormone Receptor Positive
Sign in / Sign up

Export Citation Format

Share Document